FDA Advisory Panel Endorses Semaglutide for Type 2 Diabetes FDA Advisory Panel Endorses Semaglutide for Type 2 Diabetes
Panel members said the benefits of hemoglobin A1c lowering and weight loss plus cardiovascular safety outweigh possible retinopathy risk.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Health | Heart | Weight Loss